Knights of Columbus Asset Advisors LLC Has $1.35 Million Position in ARS Pharmaceuticals, Inc. $SPRY

Knights of Columbus Asset Advisors LLC lifted its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 97.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 134,476 shares of the company’s stock after buying an additional 66,382 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in ARS Pharmaceuticals were worth $1,351,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. bought a new stake in shares of ARS Pharmaceuticals in the 2nd quarter worth approximately $30,154,000. Aberdeen Group plc lifted its position in ARS Pharmaceuticals by 49.9% in the second quarter. Aberdeen Group plc now owns 1,502,575 shares of the company’s stock worth $26,220,000 after purchasing an additional 499,916 shares during the period. Octagon Capital Advisors LP boosted its stake in ARS Pharmaceuticals by 116.0% during the second quarter. Octagon Capital Advisors LP now owns 1,350,000 shares of the company’s stock worth $23,558,000 after buying an additional 725,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in ARS Pharmaceuticals by 6.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,342,387 shares of the company’s stock valued at $23,427,000 after buying an additional 81,910 shares during the period. Finally, Rubric Capital Management LP raised its stake in shares of ARS Pharmaceuticals by 25.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,294,878 shares of the company’s stock valued at $22,596,000 after buying an additional 265,777 shares in the last quarter. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Stock Down 2.3%

NASDAQ SPRY opened at $9.99 on Friday. The stock’s 50 day simple moving average is $10.58 and its 200 day simple moving average is $11.48. ARS Pharmaceuticals, Inc. has a one year low of $6.66 and a one year high of $18.90. The firm has a market cap of $987.51 million, a PE ratio of -12.33 and a beta of 0.80. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.66 and a quick ratio of 6.51.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.07). ARS Pharmaceuticals had a negative return on equity of 38.77% and a negative net margin of 56.06%.The business had revenue of $32.50 million for the quarter, compared to the consensus estimate of $28.87 million. As a group, sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Brian Dorsey sold 21,828 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $8.71, for a total value of $190,121.88. Following the completion of the sale, the chief operating officer owned 10,789 shares of the company’s stock, valued at $93,972.19. This trade represents a 66.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Justin Chakma sold 166,380 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $8.87, for a total transaction of $1,475,790.60. The disclosure for this sale is available in the SEC filing. Company insiders own 33.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on SPRY shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Zacks Research lowered ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 27th. Finally, Roth Mkm assumed coverage on ARS Pharmaceuticals in a research report on Tuesday, November 4th. They issued a “buy” rating and a $30.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, ARS Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $33.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.